<DOC>
	<DOC>NCT02570633</DOC>
	<brief_summary>The main objective of the study is to evaluate ginger efficacy as an prophylactic treatment of migraine.</brief_summary>
	<brief_title>Ginger Capsules for the Prophylactic Treatment of Migraine</brief_title>
	<detailed_description>Patients with the diagnosis of migraine according to the IHS criteria will receive capsules of 200 mg of ginger extract (5% active ingredient) or placebo (cellulose) to be taken three times a day for 12 weeks.</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>Aged between 18 and 60 years old; Migraine diagnosis; Agree to sign the informed consent. Patients with headaches not characterized as migraine; Pregnant or lactating women; Fertile and sexually active women who do not use contraception; Abuse of painkillers, alcohol or other drugs; People with hypersensitivity to ginger compounds; People with severe neurological diseases (e.g. epilepsy) People in use of anticoagulant drugs.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Migraine</keyword>
	<keyword>Ginger</keyword>
	<keyword>Prophylactic treatment</keyword>
</DOC>